

Amendments to the Claims:


This Listing of Claims will replace all prior versions, and listings, of claims in this application:

No Admission. The claims presented below are labeled pursuant to the United States Patent and Trademark Office for convenience in examination. The cancellation of a claim or reference to a claim as "currently amended" is not an admission that the claim was altered for any reason related to patentability. None have been so altered.


Listing of Claims:

Claims 1-5 (Canceled).

Claim 6 (Previously Presented): A (2'R)-2'-deoxy-2'-fluoro-2'-C-methyl nucleoside (β -D or β -L) or its pharmaceutically acceptable salt of the structure:



wherein the Base is a pyrimidine base represented by the following formula



X is O; R¹ and R⁷ are independently H, a monophosphate, a diphosphate, a triphosphate, a H-phosphonate, alkyl, an alkyl sulfonyl, or an arylalkyl sulfonyl; and R³ is H and R⁴ is NH₂ or OH.


Claim 7 (Previously Presented): The (2'R)-2'-deoxy-2'-fluoro-2'-C-methyl nucleoside (β -D or β -L) of claim 6 or its pharmaceutically acceptable salt thereof, wherein R⁷ is H and R¹ is a monophosphate, a diphosphate, or a triphosphate.

Claim 8 (Previously Presented) The (2'R)-2'-deoxy-2'-fluoro-2'-C-methyl nucleoside (β -D) of claim 6 or its pharmaceutically acceptable salt thereof, R⁷ is H and R¹ is a diphosphate or a triphosphate.

Claim 9 (Previously Presented) The (2'R)-2'-deoxy-2'-fluoro-2'-C-methyl nucleoside (β -D or β -L) of claim 6 or its pharmaceutically acceptable salt thereof wherein R⁷ is H and R¹ is a triphosphate.

Claim 10 (Previously Presented) (2'R)-2'-deoxy-2'-fluoro-2'-C-methyl nucleoside (β -D or β -L) of claim 6 or its pharmaceutically acceptable salt thereof wherein R¹ and R⁷ are H.

Claim 11 (Previously Presented) A (2'R)-2'-deoxy-2'-fluoro-2'-C-methyl nucleoside (β -D) or its pharmaceutically acceptable salt thereof of the formula:



Claims 12-20 (Canceled).

Claim 21 (Previously Presented) A pharmaceutical composition comprising the nucleoside of claim 6 or its pharmaceutically acceptable salt and a pharmaceutically acceptable carrier.

Claim 22 (Previously Presented) A pharmaceutical composition comprising the nucleoside of claim 7 or its pharmaceutically acceptable salt and a pharmaceutically acceptable carrier.

Claim 23 (Previously Presented) A pharmaceutical composition comprising the nucleoside of claim 8 or its pharmaceutically acceptable salt and a pharmaceutically acceptable carrier.


Claim 24 (Previously Presented) A pharmaceutical composition comprising the nucleoside of claim 9 or its pharmaceutically acceptable salt and a pharmaceutically acceptable carrier.

Claim 25 (Previously Presented) A pharmaceutical composition comprising the nucleoside of claim 10 or its pharmaceutically acceptable salt and a pharmaceutically acceptable carrier.

Claim 26 (Previously Presented) A pharmaceutical composition comprising the nucleoside of claim 11 or its pharmaceutically acceptable salt and a pharmaceutically acceptable carrier.

Claims 27- 125 (Canceled).


Claim 126 (Previously Presented): A method of synthesizing the nucleoside of claim 6, which comprises glycosylating the pyrimidine with a compound having the following structure:



1-4

wherein R is lower alkyl, acyl, benzoyl, or mesyl; and Pg is selected from among C(O)-alkyl, C(O)Ph, C(O)aryl, CH₃, CH₂-alkyl, CH₂-alkenyl, CH₂Ph, CH₂-aryl, CH₂O-alkyl, CH₂O-aryl, SO₂-alkyl, SO₂-aryl, *tert*-butyldimethylsilyl, *tert*-butyldiphenylsilyl, or both Pg's may come together to form a 1,3-(1,1,3,3-tetraisopropylsiloxy)lidene).


Claim 127 (Previously Presented): A method of synthesizing the nucleoside of claim 6, which comprises selectively deprotecting a 3'-OPg or a 5'-OPg of a compound having the following structure:



wherein, each Pg is independently a protecting group selected from among C(O)-alkyl, C(O)Ph, C(O)aryl, CH₃, CH₂-alkyl, CH₂-alkenyl, CH₂Ph, CH₂-aryl, CH₂O-alkyl, CH₂O-aryl, SO₂-alkyl, SO₂-aryl, *tert*-butyldimethylsilyl, *tert*-butyldiphenylsilyl, or both Pg's may come together to form a 1,3-(1,1,3,3-tetraisopropyldisiloxanylidene).

Claims 128-129 (Canceled)

Claim 130 (Previously Presented) A (2'R)-2'-deoxy-2'-fluoro-2'-C-methyl nucleoside (β-D) or its pharmaceutically acceptable salt thereof of the formula:



Claim 131 (Previously Presented) A pharmaceutical composition comprising the nucleoside of claim 130 or its pharmaceutically acceptable salt and optionally a pharmaceutically acceptable carrier.

Claim 132 (Canceled).

Claim 133 (Canceled).

Claim 134 (Previously Presented) A liposomal composition comprising liposomes comprising the compound of claim 6 and optionally a pharmaceutically acceptable carrier.

Claim 135 (Previously Presented) A liposomal composition comprising liposomes comprising the compounds of claim 11 and optionally a pharmaceutically acceptable carrier.

Claim 136 (Previously Presented) A liposomal composition comprising liposomes comprising the compounds of claim 130 and optionally a pharmaceutically acceptable carrier.